Michael Brown - DexCom Executive Officer
| DXCM Stock | USD 84.38 0.46 0.54% |
Executive
Michael Brown is Executive Officer of DexCom Inc
| Age | 55 |
| Address | 6340 Sequence Drive, San Diego, CA, United States, 92121 |
| Phone | 858 200 0200 |
| Web | https://www.dexcom.com |
Michael Brown Latest Insider Activity
Tracking and analyzing the buying and selling activities of Michael Brown against DexCom stock is an integral part of due diligence when investing in DexCom. Michael Brown insider activity provides valuable insight into whether DexCom is net buyers or sellers over its current business cycle. Note, DexCom insiders must abide by specific rules, including filing SEC forms every time they buy or sell DexCom'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Michael Brown over six months ago Acquisition by Michael Brown of 12395 shares of Euronet Worldwide subject to Rule 16b-3 |
DexCom Management Efficiency
The company has return on total asset (ROA) of 0.0606 % which means that it generated a profit of $0.0606 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.3206 %, meaning that it created $0.3206 on every $100 dollars invested by stockholders. DexCom's management efficiency ratios could be used to measure how well DexCom manages its routine affairs as well as how well it operates its assets and liabilities. As of the 18th of January 2025, Return On Tangible Assets is likely to grow to 0.08. Also, Return On Capital Employed is likely to grow to 0.12. At this time, DexCom's Net Tangible Assets are very stable compared to the past year. As of the 18th of January 2025, Intangible Assets is likely to grow to about 162.4 M, while Intangibles To Total Assets are likely to drop 0.03.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Chantal VeillonBerteloot | Integra LifeSciences Holdings | 54 | |
| Olaf Hedrich | Medtronic PLC | N/A | |
| Mark Ploof | Medtronic PLC | N/A | |
| Jason Mills | Penumbra | N/A | |
| Jeffrey MBA | Boston Scientific Corp | 59 | |
| Melissa Mann | Inspire Medical Systems | N/A | |
| Susan Morrison | Tandem Diabetes Care | 46 | |
| Dirksen Lehman | Edwards Lifesciences Corp | N/A | |
| Trang Ly | Insulet | N/A | |
| Mark Novara | Tandem Diabetes Care | 50 | |
| June Lazaroff | Insulet | N/A | |
| Pankaj Tiwari | Penumbra | N/A | |
| Sabina Ewing | Abbott Laboratories | 51 | |
| Ezgi Yagci | Inspire Medical Systems | N/A | |
| Ben Sorci | Penumbra | N/A | |
| Arnold Pinkston | Edwards Lifesciences Corp | 65 | |
| Libba Sapitsky | Tandem Diabetes Care | N/A | |
| Arnold JD | Edwards Lifesciences Corp | 66 | |
| Mei Jiang | Medtronic PLC | N/A | |
| Torod Neptune | Medtronic PLC | N/A | |
| Jordan MD | Tandem Diabetes Care | N/A | |
Management Performance
| Return On Equity | 0.32 | ||||
| Return On Asset | 0.0606 |
DexCom Inc Leadership Team
Elected by the shareholders, the DexCom's board of directors comprises two types of representatives: DexCom inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DexCom. The board's role is to monitor DexCom's management team and ensure that shareholders' interests are well served. DexCom's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DexCom's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Shelly Selvaraj, Senior Officer | ||
| Leverne Marsh, Executive Marketing | ||
| Matthew Dolan, Corporate Strategy | ||
| Teri Lawver, Executive Officer | ||
| Jacob Leach, Executive COO | ||
| Donald Abbey, Quality Services | ||
| Jereme Sylvain, CFO VP | ||
| Jereme CPA, CFO VP | ||
| Paul Flynn, Ex Revenue | ||
| Kevin Sayer, CEO and President and Director | ||
| Girish Naganathan, Executive CTO | ||
| Michael Brown, Executive Officer | ||
| Stacey Stewart, Senior Officer | ||
| Sadie Stern, Executive Officer | ||
| Steven Pacelli, Executive VP of Strategy and Corporate Devel. | ||
| Sean Christensen, Director Relations | ||
| Andrew Balo, Senior Vice President - Clinical and Regulatory Affairs |
DexCom Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is DexCom a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.32 | ||||
| Return On Asset | 0.0606 | ||||
| Profit Margin | 0.17 % | ||||
| Operating Margin | 0.15 % | ||||
| Current Valuation | 33.24 B | ||||
| Shares Outstanding | 390.6 M | ||||
| Shares Owned By Insiders | 0.31 % | ||||
| Shares Owned By Institutions | 96.94 % | ||||
| Number Of Shares Shorted | 8.8 M | ||||
| Price To Earning | 245.31 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DexCom Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DexCom. If investors know DexCom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DexCom listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.157 | Earnings Share 1.64 | Revenue Per Share | Quarterly Revenue Growth 0.02 | Return On Assets |
The market value of DexCom Inc is measured differently than its book value, which is the value of DexCom that is recorded on the company's balance sheet. Investors also form their own opinion of DexCom's value that differs from its market value or its book value, called intrinsic value, which is DexCom's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DexCom's market value can be influenced by many factors that don't directly affect DexCom's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DexCom's value and its price as these two are different measures arrived at by different means. Investors typically determine if DexCom is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DexCom's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.